The Most Expensive Decision Might Be the One You Didn't Make

TLDR

Two operators can meet the same regulatory standard today and be in very different positions tomorrow. The difference may come down to decisions made years before the market needed them.

Building ahead of regulation can create an advantage that competitors cannot quickly buy. But the real skill is knowing which capabilities are worth funding before the return is visible.

---

Europe's pharmaceutical rules are not merely a compliance burden.

They forced cannabis operators to make decisions years ago that are beginning to determine who can compete today.

Think about two teams building manufacturing facilities.

Both have limited capital. Both need to get operational. Both understand the current regulatory requirements.

One builds to meet the standards in front of them.

The other spends additional capital on equipment, laboratory capabilities, testing infrastructure, and processes it believes will be necessary as the market matures.

At the time, the second team may look like it made the worse decision.

More capital committed. Longer timelines. Less flexibility. No immediate revenue to justify the additional expense.

And we've already seen the other side of this in cannabis.

Operators spent enormous amounts of capital building facilities around expectations that never materialized. Some built capacity the market couldn't support. Others invested in infrastructure that became a financial burden rather than a competitive advantage.

So how do you distinguish between building too early and building something your competitors will eventually need years to replicate?

The Testing Decision Operators Are Avoiding

One of the most interesting parts of my conversation with Michael Sassano was the difference between internal pharmaceutical testing and the third-party testing model most U.S. cannabis operators know.

Michael explained that SOMAI operates its own laboratory, validates its products, and generates its own certificates of analysis within its pharmaceutical quality system.

When I asked whether that investment was worth it, his response was direct:

"At our level, it's mandatory because we're dealing with pharmaceutical players out there and they want you to own all of your data."

That distinction matters.

In the U.S., operators have become accustomed to sending samples to third-party laboratories to satisfy state testing requirements.

But knowing whether a finished batch passed is different from understanding what happened throughout production.

An internal laboratory can provide greater control over methods, product development, and quality data. Better process measurement can help operators identify variation earlier and investigate problems faster.

This is something we think about at Newton Insights.

When operators have more visibility into their processes, they have more information to make decisions. Not simply whether a product passed a test, but whether production is behaving the way they expected.

The value is not collecting more data. It is having the ability to act on it.

And that capability takes time to develop.

Michael described how SOMAI planned for products such as concentrates, rosin, and hash years before they were ready to enter the market.

Equipment qualification, process validation, stability studies, and regulatory documentation all have to come together before commercial launch.

The work had to begin before the opportunity was ready.

Now consider the regulatory direction.

The U.S. has been debating Schedule III rescheduling, while pharmaceutical manufacturing already operates under more demanding quality and documentation frameworks.

Rescheduling alone would not automatically impose Europe's pharmaceutical requirements on state cannabis operators.

But if the FDA eventually takes a more direct role in regulating certain cannabis products through pharmaceutical pathways, the capabilities required to participate could look very different from those many operators rely on today.

Michael made that distinction himself. A stricter FDA pharmaceutical pathway could require a substantially different approach to manufacturing, validation, and regulatory documentation.

That creates a decision operators cannot ignore.

Invest today in better testing, process visibility, and quality systems, even when current rules don't require all of them?

Or wait until the commercial or regulatory case becomes unavoidable?

Most operators have good reasons to wait.

Capital is limited. Internal testing is expensive. Changing established processes is difficult. And third-party testing obligations don't disappear simply because a company invests in its own capabilities.

But waiting for certainty can mean starting years behind the operators who prepared.

The Difference Between Spending and Building

Building ahead of regulation is not automatically intelligent.

The distinction is whether the investment creates a capability the business can use, even if the exact regulatory outcome never arrives.

Better testing and process control can create value today. But those investments alone don't guarantee a profitable business.

A facility can be compliant and still have no customers.

The product still needs market access, distribution, and a route to the patient.

Michael's broader argument about Europe reinforces this. Manufacturing capability matters, but controlling more of the commercial route can provide greater influence over margins than simply supplying product to intermediaries.

The advantage is not just having the right facility. It is having the right capabilities connected to a business that can monetize them.

What Are You Really Saving?

For operators managing limited capital, this creates a difficult question.

When you choose not to invest in a capability today, how much are you actually saving?

There is the immediate capital you preserve.

But there may also be a future cost.

The time required to build that capability later. The opportunity you cannot pursue while waiting. The customers who establish relationships with competitors already prepared to serve them.

Not every operator can afford to build years ahead. Nor should they.

But capital discipline cannot mean evaluating every investment only against today's requirements.

Sometimes the cheaper decision is simply the one whose cost has not arrived yet.

That is the part I keep coming back to.

Two operators can look almost identical today. Similar products. Similar facilities. Similar markets.

Yet decisions made years earlier may determine which one can respond when the next opportunity arrives.

The question is not whether you can afford to build ahead of the market.

It is whether you can afford to start building only after the market tells you to.